NEW YORK, NY / ACCESSWIRE / December 28, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
ZSAN Shareholders Click Here: https://www.zlk.com/pslra-1/zosano-pharma-corporation-loss-submission-form?prid=11811&wire=1
SPLK Shareholders Click Here: https://www.zlk.com/pslra-1/splunk-inc-loss-submission-form?prid=11811&wire=1
GDRX Shareholders Click Here: https://www.zlk.com/pslra-1/goodrx-holdings-inc-loss-submission-form?prid=11811&wire=1
* ADDITIONAL INFORMATION BELOW *
Zosano Pharma Corporation (NASDAQ:ZSAN)
ZSAN Lawsuit on behalf of: investors who purchased February 13, 2017 - September 30, 2020
Lead Plaintiff Deadline : December 28, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/zosano-pharma-corporation-loss-submission-form?prid=11811&wire=1
According to the filed complaint, during the class period, Zosano Pharma Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company's New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company's lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
Splunk Inc. (NASDAQ:SPLK)
SPLK Lawsuit on behalf of: investors who purchased October 21, 2020 - December 2, 2020
Lead Plaintiff Deadline : February 2, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/splunk-inc-loss-submission-form?prid=11811&wire=1
According to the filed complaint, during the class period, Splunk Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Splunk was not closing deals with its largest customers in the third fiscal quarter of 2021; (2) Splunk was not hitting the financial targets it had previously announced; and (3) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
GoodRx Holdings, Inc (NASDAQ:GDRX)
GDRX Lawsuit on behalf of: investors who purchased September 23, 2020 - November 16, 2020
Lead Plaintiff Deadline : February 16, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/goodrx-holdings-inc-loss-submission-form?prid=11811&wire=1
According to the filed complaint, during the class period, GoodRx Holdings, Inc made materially false and/or misleading statements and/or failed to disclose that: at the time of the IPO, unbeknownst to investors, Amazon.com, Inc. was developing and would soon introduce its own online and mobile prescription medication ordering and fulfillment service that would directly compete with GoodRx. Defendants timed the IPO so that it was priced before Amazon announced its online pharmaceutical business to facilitate the IPO and create artificial demand for the common shares sold therein, as well to maximize the amount of money the Company and the selling stockholders could raise in the IPO. Given defendants' knowledge of Amazon's intention to enter the online pharmaceutical business, and their misleading statements about GoodRx's competitive position made contemporaneously with that knowledge, defendants' materially false and/or misleading statements alleged herein were made willfully and caused GoodRx common stock to trade at artificially inflated prices during the Class Period.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP